Drugs / AnAPN1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05905432 | Sep 2023 → Jan 2025 | malaria | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AnAPN1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905432 ↗ |
| Known as | UF6b | “The AnAPN1 vaccine consists of the AnAPN1 dimer antigen construct (UF6b) construct derived from the sequence of a protein of the mosquito midgut (Anopheles gambiae alanyl...” NCT05905432 ↗ |
| Modality | Protein / enzyme biologic | “AnAPN1 is a recombinant protein expressed in Escherichia coli.” NCT05905432 ↗ |
| Route | Intramuscular | “Route of administration is intramuscular.” NCT05905432 ↗ |